Keep Pace with Advanced Cancer Treatments
ORDER GUARDANT360 CDx TEST KITS
KRAS G12C is now actionable as a result of the FDA approval of sotorasib (LUMAKRASTM) for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have received at least one prior systemic therapy.1
KRAS is the most frequently mutated oncogene in human cancers.2  
KRAS G12C, the most common type of KRAS mutation, is a point mutation at codon 12 that causes a glycine to cysteine amino acid substitution.3,4
13% of patients with advanced NSCLC harbor a KRAS G12C mutation5
~25,000 NSCLC patients with a KRAS G12C mutation are diagnosed each year in the US4
Now there are 9 guideline-recommended biomarkers for mNSCLC.
KRAS
EGFR
ALK
ROS1
BRAF
RET
MET
NTRK
ERBB2
(HER2)
Biomarkers with
FDA-approved targeted therapy
Emerging biomarkers with promising clinical data
With the FDA approval of sotorasib, 2 out of 3 mNSCLC patients will have an actionable biomarker for targeted therapy.
The approval underscores the need for comprehensive genomic profiling of all patients.
Prevalence of patients who many benefit by treatment type
Up to
64%
of patients with NSCLC have identifiable driver mutations6
Draw blood first. Make plans fast.
Guardant360 CDx is a fast and reliable way to identify the 64% of NSCLC patients with a driver mutation.6  As the first FDA-approved comprehensive liquid biopsy for all solid tumors, Guardant360 CDx  delivers results in just 7 days. We make it easy to leverage guideline-complete genomic profiling to inform treatment decisions, especially for the 1 in 8 patients with a KRAS G12C mutation.2
Inform treatment decisions with guideline-complete genomic profiling
Our Medical Affairs team can provide a list of your KRAS G12C patients.
Find KRAS G12C Patients
To start testing with Guardant360 CDx liquid biopsy, request kits to be sent to your office immediately.
Order Guardant360 CDx Kits
We are happy to answer clinical questions about Guardant360 CDx and our easy to interpret report.
Request an In-Service
Guardant360 CDx is:
First FDA-approved comprehensive liquid biopsy
Complete genomic results in 7 days
Medicare-covered for all solid tumors, regardless of tissue availability
Treat with Confidence
Guardant360 CDx identifies patients who may benefit from sotorasib and other targeted therapies, with results reported in just 7 days.
1. LUMAKRAS™ prescribing information. Thousand Oaks, CA: Amgen; 2021.
2. Analysis of AACR Genie v8.
3. Arbour KC, et al. Clin Cancer Res. 2018;24:334-340.
4. Ihle NT, et al. J Natl Cancer Inst. 2012;104:228-239.
5. Hong DS et al. N Engl J Med. 2021; 384:185-187.
6. Pakkala S et al. JCI Insight. 2018; 3(15):e120858.